Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain
| Autor: | Linda Wase, Ashraf S. Habib, Sergio D. Bergese, Keith A. Candiotti, Cathy Michalsky, Mark A. Demitrack, Peter H. Pan, Michael H. Bourne, Marek Brzezinski, Gregory B. Hammer |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
business.industry
Incidence (epidemiology) Oliceridine Biased opioid Postoperative pain Anesthesiology and Pain Medicine Opioid Concomitant Naloxone Anesthesia Medicine Respiratory depression Neurology (clinical) Dosing Bolus (digestion) Analgesia business Body mass index Depression (differential diagnoses) medicine.drug |
| Zdroj: | Pain and therapy, vol 10, iss 1 |
| Popis: | IntroductionAdvanced age and obesity are reported to increase the risk of opioid-induced respiratory depression (OIRD). Oliceridine, an intravenous opioid, is a G-protein-biased agonist at the µ-opioid receptor that may provide improved safety. The recent phase 3 ATHENA open-label, multicenter study evaluated postoperative use of oliceridine in patients with moderate-to-severe acute pain. This exploratory analysis of the ATHENA data examined the incidence of OIRD in older (≥ 65years) and/or obese (BMI ≥ 30kg/m2) patients and analyzed risk factors of OIRD.MethodsPatients aged ≥ 18years with a score ≥ 4 on an 11-point numeric pain rating scale (NPRS) received IV oliceridine as needed via bolus dosing and/or patient-controlled analgesia (PCA). OIRD occurring within 48h of last dose of oliceridine was defined using two established definitions: (1) naloxone use, (2) respiratory rate |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|